The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture of chemicals and pharmaceuticals Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
170 - 192 jobs Number of planned job losses
Announcement Date
15 January 2025
Employment effect (start)
Foreseen end date
Description
Novartis, a Swiss-based pharmaceutical multinational, has announced it will be dismissing 170 employees at its facility in Puurs. The company management stated that it intends to increase the competitiveness of the facility through restructuring measures. In addition to the reduction in staffing, there is also the intention to invest 40 million euros in the site to further expand its production capabilities for biologicals. Trade unions at the facility are very critical of the decision by the company management, as the company is considered to be profitable.
Eurofound (2025), Novartis, Internal restructuring in Belgium, factsheet number 202348, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/202348.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
